G6PD and G6PD deficiency: It could be hypothesized that the prolongation of the outbreak with a second peak (Fig 2), despite several stringent measures as directly-observed treatment (DOT), organization of regular active case detection (ACD) and even two mass drug administration (MDA) events, reaching almost 90% of the residing population, was fueled by relapses from patients, who did not receive Primaquine because of a pregnancy, breastfeeding or glucose-6-phosphate dehydrogenase (G6PD) deficiency.